The facility will produce parenteral products and delivery devices and is set to create 460 new jobs.
Eli Lilly and Company announced on Jan. 21, 2020 that it will invest more than $470 million into a new pharmaceutical manufacturing facility in Durham, NC's Research Triangle Park.
The new facility will produce parenteral products and delivery devices, according to a company press release. The project will also create 460 new jobs in positions such as scientists, engineers, quality professionals, and manufacturing operations. Many of the new positions will be accompanied by salaries of $72,000 and more, which is higher than the average wage in Durham County of $71,756.
"This next-generation manufacturing facility will allow us to expand our capacity to make the Lilly medicines that are helping people with serious illnesses today, and help us prepare for new medicines coming from our robust pipeline in the future," said David A. Ricks, chairman and CEO of Lilly, in the press release. "In the past two years, we have invested billions of capital in new US-based manufacturing because the 2017 tax reform rebalanced the playing field in favor of the American worker. We're excited to be bringing more of these high-skill, high-wage advanced manufacturing jobs to North Carolina."
Source: Eli Lilly
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.